Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US10858364B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 21, 2017 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | Dec 21, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
In some embodiments, the invention relates to the compounds of Formula (I) and (II) or a pharmaceutically acceptable salt thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, in some embodiments, the present invention relates to the compounds of Formula (I) and (II), pharmaceutical compositions thereof, and the use of the compounds and pharmaceutical compositions in the treatment of a hyperproliferative disorder, an inflammatory disorder, an immune disorder, or an autoimmune disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.